Prevnar 20, the successor to Pfizer's blockbuster Prevnar 13, and Vaxneuvance were approved back-to-back by the FDA in June 2021 and July 2021, respectively. Since then, Prevnar 13’s market share has been cannibalized to an extent as both vaccines are now recommended by the Advisory Committee on Immunization Practices at parity – superseding prior recommendations for Prevnar 13 in elderly populations in the US – with a sequential dose of Merck’s Pneumovax 23 being required when Vaxneuvance is used. European approval has also been granted to both Vaxneuvance and Prevnar 20 (as Apexxnar) for use in adults, and guidelines in the five major European markets (France, Germany, Italy, Spain, and the UK) are beginning to include recommendations for Vaxneuvance in infants and for Prevnar 20 in the elderly. 

This Datamonitor Healthcare report contains a Disease Analysis module.